Nuformix PLC NXP002 data to be presented at 2022 ERS Congress

TIDMNFX

Nuformix PLC

05 July 2022

Reach

5 July 2022

Nuformix plc

("Nuformix" or the "Company" or the "Group")

NXP002 data to be presented at the 2022 European Respiratory Society Congress

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that both of the abstracts submitted for presentation at the European Respiratory Society ("ERS") International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation. NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").

Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: " We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases ("ILDs") . The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs. We are therefore delighted that the abstracts describing our initial work have been accepted following peer review.

"The ERS is a leading international respiratory congress. It provides us the opportunity to share these positive data with the scientific and clinical communities and, very importantly, the congress is attended by all the major respiratory-focused pharmaceutical companies. Ultimately, we will be looking to license NXP002 and the congress offers us an important opportunity to present and introduce NXP002 to potential licensing partners."

Enquiries:

 
 Nuformix plc 
 Dr Julian Gilbert, Non-executive           Via IFC Advisory 
  Director 
  Maddy Kennedy, Non-executive Director 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  [phone] 
 John Howes (Corporate Broking)             [phone] 
 IFC Advisory Limited 
 Tim Metcalfe                               [phone] 
  Zach Cohen                                 [e-mail] 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRARIMRTMTTMMMT

(END) Dow Jones Newswires

July 05, 2022 02:00 ET (06:00 GMT)